Tocilizumab as monotherapy is clinically more effective than adalimumab
Kreutzkamp, B.
Medizinische Monatsschrift für Pharmazeuten 36(9): 356-357
2013
ISSN/ISBN: 0342-9601 PMID: 24069651 Document Number: 669266
Document emailed within 1 workday
Related Documents
Miller, D.W.; Koch, S.B.; Yentzer, B.A.; Clark, A.R.; O'Neill, J.R.; Fountain, J.; Weber, T.M.; Fleischer, A.B. 2011: An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial Journal of Drugs in Dermatology: Jdd 10(5): 531-537Konradsen, H.B. 2001: Pneumococcal vaccine is clinically effective Ugeskrift for Laeger 163(48): 6771-6774
Tudyka, J.; Kratzer, W.; Janowitz, P.; Mason, R.; Wechsler, J.G. 1995: Combined bile acid therapy is more effective on biliary lipids and dissolution rates than monotherapy after gallstone lithotripsy American Journal of Gastroenterology 90(11): 1942-1948
Laughlin, W.J. 1998: Clinically appropriate, cost-effective MR scan of the acute knee injury Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 150(7): 308-311
Pereira, C.A.P.; Petrilli, A.S.ér.; Carlesse, F.A.; Luisi, F.áv.A.V.; da Silva, K.át.V.ôn.T.B.; de Martino Lee, M.L.úc. 2009: Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison Journal of Microbiology Immunology and Infection 42(2): 141-147
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Parker, J.O.; Amies, M.H.; Hawkinson, R.W.; Heilman, J.M.; Hougham, A.J.; Vollmer, M.C.; Wilson, R.R. 1995: Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group Circulation 91(5): 1368-1374
Luque, A.E.; Cohn, S.E.; Park, J.-G.; Cramer, Y.; Weinberg, A.; Livingston, E.; Klingman, K.L.; Aweeka, F.; Watts, D.H. 2015: Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study Antimicrobial Agents and ChemoTherapy 59(4): 2094-2101
Brandão, F.M.; Coelho, P.; Pinto, P.; Combe, B. 2010: Tocilizumab - a new step in rheumatoid arthritis treatment Acta Reumatologica Portuguesa 35(3): 302-312
Papo, M.; Bielefeld, P.; Vallet, H.él.èn.; Seve, P.; Wechsler, B.; Cacoub, P.; Le Hoang, P.; Papo, T.; Bodaghi, B.; Saadoun, D. 2014: Tocilizumab in severe and refractory non-infectious uveitis Clinical and Experimental Rheumatology 32(4 Suppl 84: S75-S79
Sallés, M.; Mínguez, S.; Ros, S.; Tuneu, R.; Gelman, S.M. 2017: Sustained response to tocilizumab in a patient with relapsing polychondritis complicated by aortitis Clinical and Experimental Rheumatology 35 Suppl 103(1): 223
Van Herwaarden, N.; Herfkens-Hol, S.; van der Maas, A.; van den Bemt, B.J.F.; van Vollenhoven, R.F.; Bijlsma, J.W.J.; den Broeder, A.A. 2014: Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity Clinical and Experimental Rheumatology 32(3): 390-394
Calvo-Río, V.; de la Hera, D.; Beltrán-Catalán, E.; Blanco, R.; Hernandez, M.; Martínez-Costa, Lía.; Loricera, J.; Cañal, Jín.; Ventosa, J.; Ortiz-Sanjuán, F.; Pina, T.; González-Vela, M.Carmen.; Rodríguez-Cundín, P.; González-Gay, M.A. 2014: Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review Clinical and Experimental Rheumatology 32(4 Suppl. 84): S54-S57
Ortiz Pérez, S.; Caro Teller, J.é M.; García Muñoz, C.; Herraiz Robles, P.; Lozano Morillo, F.; Pablos Álvarez, J.é L.; Ferrari Piquero, J.é M. 2021: Controlled supply of tocilizumab during the COVID-19 pandemic and its influence on the treatment of rheumatological patients Revista Espanola de Salud Publica 95
Spertini, F.ço. 2017: Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab Revue Medicale Suisse 13(544-545): 20-22
Manfredi, A.; Sebastiani, M.; Cassone, G.; Colaci, M.; Sandri, G.; Ferri, C. 2018: Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series Clinical and Experimental Rheumatology 36(2): 342
Nasonov, E.L. 2010: New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor) Terapevticheskii Arkhiv 82(5): 64-71
Terenzi, R.; Santoboni, G.; Bartoloni, E.; Alunno, A.; Luccioli, F.; Gerli, R. 2015: Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study Clinical and Experimental Rheumatology 33(3): 445
Lane, T.; Gillmore, J.D.; Wechalekar, A.D.; Hawkins, P.N.; Lachmann, H.J. 2015: Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature Clinical and Experimental Rheumatology 33(6 Suppl. 94): S46-S53
George, S.J.; Anderson, H.L.; Hsu, S. 2006: Adalimumab-induced urticaria Dermatology Online Journal 12(2): 4